Title: Predictive factors for metabolic syndrome in patients with Metabolic dysfunction-
associated steatotic liver disease (MASLD)
Version: 3 Date: 22 Jun 2025
Reviewer's report:
• In Table 1, patients took only glimepiride among sulfonylureas, only sitagliptin among DPP-4
inhibitors, or only dapagliflozin among SGLT-2 inhibitors, and did not take any other drugs
containing active substances from these groups (e.g., gliclazide, liraglutide or empagliflozine)?
• Among the complications of diabetes, was the rate of cardiovascular complications in patients
not examined? If not, why wasn't it investigated?
• How do you explain that HbA1c was not significantly associated with the presence of metabolic
syndrome? Please describe this in a few sentences.
• Please clarify references 3, 16, 21, 25, 31 and 33.
Title: Predictive factors for metabolic syndrome in patients with Metabolic dysfunction-
associated steatotic liver disease (MASLD)
Version: 3 Date: 22 Jun 2025
Reviewer's report:
• In Table 1, patients took only glimepiride among sulfonylureas, only sitagliptin among DPP-4
inhibitors, or only dapagliflozin among SGLT-2 inhibitors, and did not take any other drugs
containing active substances from these groups (e.g., gliclazide, liraglutide or empagliflozine)?
• Among the complications of diabetes, was the rate of cardiovascular complications in patients
not examined? If not, why wasn't it investigated?
• How do you explain that HbA1c was not significantly associated with the presence of metabolic
syndrome? Please describe this in a few sentences.
• Please clarify references 3, 16, 21, 25, 31 and 33.
Please review this paper.
user
Title: Predictive factors for metabolic syndrome in patients with Metabolic dysfunction-
associated steatotic liver disease (MASLD)
Version: 3 Date: 22 Jun 2025
Reviewer's report:
• In Table 1, patients took only glimepiride among sulfonylureas, only sitagliptin among DPP-4
inhibitors, or only dapagliflozin among SGLT-2 inhibitors, and did not take any other drugs
containing active substances from these groups (e.g., gliclazide, liraglutide or empagliflozine)?
• Among the complications of diabetes, was the rate of cardiovascular complications in patients
not examined? If not, why wasn't it investigated?
• How do you explain that HbA1c was not significantly associated with the presence of metabolic
syndrome? Please describe this in a few sentences.
• Please clarify references 3, 16, 21, 25, 31 and 33.
assistant